The FreeStyle Libre 3, made by Abbott, is a continuous glucose monitoring (CGM) system that measures glucose levels in the fluid just beneath your skin and sends readings to your smartphone every minute. It is currently the smallest and thinnest CGM sensor on the market, about the size of two stacked pennies, and it lasts 14 days before needing replacement. The device has become one of the most widely used CGMs worldwide for people with type 1 and type 2 diabetes, though its reach is expanding into non-diabetic populations as well.
How the Sensor Measures Glucose
The Libre 3 sensor sits on the back of your upper arm, held in place by a small adhesive patch. A tiny, flexible filament extends just under the skin into the interstitial fluid, which is the thin layer of fluid surrounding your cells. That filament contains an electrochemical sensor coated with glucose oxidase, an enzyme that reacts with glucose and generates a small electrical signal. The strength of that signal corresponds to how much glucose is present, and the sensor’s onboard electronics convert it into a glucose reading.
One thing worth understanding is that the sensor is not reading your blood glucose directly. It is reading glucose in interstitial fluid, which lags slightly behind what is happening in your bloodstream. Research has measured this physiological delay at roughly five to six minutes in healthy fasting adults.
1PubMed Central. Time lag of glucose from intravascular to interstitial compartment in humansIn practice, this means that if your blood sugar is rising or falling quickly, say after a meal or during intense exercise, the number on your phone may not perfectly match a fingerstick reading taken at the same moment. The lag is usually small enough to be clinically irrelevant during stable glucose periods, but it is worth keeping in mind during rapid changes.
Real-Time Data Without Scanning
The Libre 3 differs from its predecessors in a significant way. The original FreeStyle Libre and Libre 2 required you to scan the sensor with your phone or a dedicated reader to see your glucose value. The Libre 3 eliminated that step entirely. It streams glucose data via Bluetooth to a compatible smartphone app every single minute, delivering a continuous real-time glucose trace without any user action required.
This change matters most for alarms. Because the sensor is always transmitting, the Libre 3 can alert you when your glucose drops below or rises above thresholds you set. You do not have to remember to scan, and you do not have to be awake. Overnight low-glucose alarms are one of the features people with type 1 diabetes value most, since hypoglycemia during sleep is both common and dangerous.
Accuracy Numbers and What They Mean
The standard measure of CGM accuracy is called MARD, which stands for mean absolute relative difference. It is essentially the average percentage by which the sensor’s reading differs from a lab-quality reference measurement. A lower MARD is better, and anything under about 10% is generally considered clinically reliable.
In a clinical study of participants aged six and older, the Libre 3 achieved an overall MARD of 7.8%, with about 93% of readings falling within 20% or 20 mg/dL of the reference value. Performance remained stable across the full 14-day wear period. In younger children aged four to five, accuracy was slightly lower, with a MARD of 10.0% and about 89% of readings meeting that same benchmark.
2PubMed Central. Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring SystemThose numbers look good in isolation, but the real question most people have is how the Libre 3 stacks up against its main competitor, the Dexcom G7. A head-to-head comparison found the Libre 3 had a significantly lower MARD than the Dexcom G7 (about 9% versus nearly 14%), with a larger share of readings in the accurate zone (roughly 91% versus 79%). The two sensors performed similarly during the first 12 hours after insertion, but the Libre 3 pulled ahead in accuracy after that initial warm-up window.
3PubMed Central. Comparison of Point Accuracy Between Two Widely Used Continuous Glucose Monitoring SystemsWhere Accuracy Falls Short
No CGM is perfect, and the Libre 3 has a specific weak spot that matters clinically: detecting low blood sugar. A 2025 comparison of three major CGM systems found that the Libre 3 detected about 73% of true low-glucose events, compared to 80% for the Dexcom G7 and 93% for the Medtronic Simplera.
4Journal of Diabetes Science and Technology. CGM Accuracy Comparison 2025: Dexcom G7 vs FreeStyle Libre 3 vs Medtronic SimpleraMissing roughly one in four lows is not catastrophic, but it does mean you should not rely entirely on the Libre 3 alarm to catch every hypoglycemic episode. If you tend to have frequent or severe lows, or if you use an automated insulin delivery system where the CGM reading directly controls insulin dosing, the missed-low rate is worth discussing with your care team.
Another accuracy issue that affects all CGMs, including the Libre 3, is pressure-induced sensor attenuation. If you sleep on the arm where the sensor is placed, or compress it during exercise, the pressure can cause the sensor to report falsely low glucose values. These drops look like real hypoglycemia on the graph and can trigger alarms or, in systems connected to insulin pumps, cause the pump to reduce or stop insulin delivery when it should not.
5PubMed Central. Prospective Detection of Hypoglycemia and Near-Hypoglycemia Inducing Pressure-Induced Sensor Attenuation Onset in Continuous Glucose Monitoring Time SeriesIf you notice a sudden, unexplained glucose drop, especially one that happens while you are lying down or leaning on the sensor arm, it is often worth confirming with a fingerstick before treating with fast-acting carbohydrates.
Accuracy During Exercise
People with diabetes who exercise regularly want to know whether the Libre 3 stays reliable when their body is under physical stress. A study of women with type 1 diabetes found that the sensor’s accuracy during moderate-intensity continuous aerobic exercise was reasonable, with MARD values in the 14–18% range before and after exercise sessions. The readings were not affected by which phase of the menstrual cycle participants were in.
6PubMed. Accuracy of FreeStyle Libre 3 During Moderate-Intensity Continuous Aerobic Exercise at Different Phases of the Menstrual Cycle in Females with Type 1 DiabetesThose MARD values are noticeably higher than the 7.8% overall figure from resting clinical trials, which makes sense: exercise increases blood flow and changes how quickly glucose moves between blood and interstitial fluid. The sensor is still useful during workouts for tracking trends, like whether your glucose is heading up or down, but individual point readings are less precise during and immediately after activity. Many endocrinologists suggest setting your low alarm threshold a bit higher before a workout as a buffer against this reduced accuracy.
An even more extreme scenario was tested during recreational scuba diving. In that environment, the Libre 3 held up considerably better than the Dexcom G7, with an overall MARD of about 14% compared to 31% for the G7. Nearly all of the Libre 3 readings fell in a safe clinical accuracy zone, and it performed substantially better at identifying hypoglycemia during dives.
7PubMed. Continuous Glucose Monitoring and Recreational Scuba Diving in Type 1 Diabetes: Head-to-Head Comparison Between Free Style Libre 3 and Dexcom G7 PerformanceWhat Wearing a CGM Actually Does for Your Health
Having real-time glucose data changes behavior in ways that improve outcomes. A large real-world study of people using insulin-treated diabetes found that starting CGM brought average HbA1c down from about 8.2% to 7.1%, and more than half of those who started above 7% saw their HbA1c drop by at least a full percentage point.
8PubMed Central. Change in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark StudyA separate analysis focusing specifically on type 2 diabetes found that CGM users, compared to those doing traditional fingerstick monitoring, spent about 15 percentage points more time in their target glucose range. They also used less insulin, lost more weight, and reported better satisfaction with their diabetes management.
9PubMed Central. Time in range—A new gold standard in type 2 diabetes research?A meta-analysis of randomized trials across both type 1 and type 2 diabetes found more modest but consistent average improvements: roughly a 0.17% drop in HbA1c, about 70 extra minutes per day spent in the target glucose range, and equal reductions in time spent both too high and too low.
10Diabetes & Metabolism Journal. Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic ControlThe gap between the real-world study’s dramatic HbA1c drop and the controlled trials’ smaller average effect size probably reflects a difference in who benefits most. People with the worst glucose control at baseline tend to see the biggest improvement, and real-world studies often capture exactly those people. Controlled trials, by contrast, enroll more varied populations and shorter follow-up periods, which dilutes the effect. The point is that CGM helps, and it helps the most if your control is currently poor.
Cost and Insurance Coverage
The out-of-pocket price of the Libre 3 varies widely depending on your insurance, your pharmacy, and where you live. Without insurance in the United States, a single 14-day sensor typically costs somewhere in the range of $70 to $85, which works out to roughly $140 to $170 per month. Many commercial insurance plans and pharmacy benefit managers cover it with a copay, but the amount varies.
Medicare coverage has specific eligibility requirements. You need a diabetes diagnosis, you must be using insulin or have problematic hypoglycemia, and you need to have had a qualifying visit with your healthcare provider within six months of ordering the sensor. Most Medicare Advantage plans cover the Libre 3 at no cost at the pharmacy. Under Original Medicare, you may need to cover 20% of the Medicare-approved amount after your deductible.
11Abbott. FreeStyle Libre Systems Medicare CoverageOne cost consideration people sometimes overlook is the cumulative nature of CGM spending. Even a $35 monthly copay adds up to $420 per year, indefinitely, because the sensors are disposable. Unlike a blood glucose meter that you buy once and then purchase inexpensive test strips for, CGM is a subscription-like expense. That said, many users find the trade-off worthwhile given the health improvements and the elimination of multiple daily fingersticks.
Skin Reactions and the Adhesive Problem
Any device that sticks to your skin for two weeks straight can irritate it, and the Libre sensors have a well-documented track record of causing contact dermatitis in a subset of users. Estimates put the rate of skin reactions somewhere between about 4% and 8%.
12Actas Dermo-Sifiliográficas. Skin Reactions to Glucose Sensors: Present and FutureThe main culprit has been identified as isobornyl acrylate, a chemical used in the adhesive. In studies of patients who developed skin reactions to the FreeStyle Libre, a large majority tested positive for allergy to this compound. Reactions typically appear as redness, itching, and sometimes blistering at the sensor site, and they tend to worsen with repeated sensor applications if the person has become sensitized.
12Actas Dermo-Sifiliográficas. Skin Reactions to Glucose Sensors: Present and FutureIf you develop persistent skin irritation, there are workarounds. Some users apply a thin barrier film or hydrocolloid dressing to the skin before placing the sensor, creating a protective layer between the adhesive and the skin. Others rotate placement sites more aggressively. For people with confirmed allergic contact dermatitis to isobornyl acrylate, switching to a different CGM system may be necessary, since other manufacturers use different adhesive chemistries.
Use by People Without Diabetes
An increasingly visible trend is non-diabetic people wearing CGMs like the Libre 3, particularly athletes and people interested in metabolic health optimization. The appeal is straightforward: seeing how your glucose responds to specific foods, exercise, sleep patterns, and stress in real time can inform dietary and training decisions in ways that periodic lab work cannot.
The evidence for this use case is still thin. A study of healthy young adults wearing a CGM during strength training found that the device showed satisfactory accuracy for tracking glucose trends but varied substantially between individuals and did not meet the clinical accuracy standards required for diabetic monitoring. The researchers concluded that while CGM shows potential for gathering and interpreting glucose data in sports nutrition, the application is not yet validated, and challenges in interpreting the data could limit its usefulness.
13PubMed Central. Accuracy of a continuous glucose monitoring system applied before, during, and after an intense leg-squat session with low- and high-carbohydrate availability in young adults without diabetesThe fundamental challenge is that glucose fluctuations in non-diabetic people are much smaller, typically staying within a relatively narrow band. The sensor’s margin of error, which is clinically acceptable for someone whose glucose swings between 50 and 350 mg/dL, starts to feel large when you are trying to detect the difference between 95 and 110 mg/dL after eating a banana versus a bagel. The signal-to-noise ratio shrinks, and meaningful conclusions become harder to draw.
There is also a psychological dimension. Some clinicians have raised concerns about non-diabetic users developing anxiety around normal, healthy glucose fluctuations. A spike to 160 mg/dL after a carbohydrate-rich meal, for instance, is entirely physiological and harmless in a person with functioning insulin response, but it can look alarming on a CGM graph if you do not have the context to interpret it.
The Environmental Footprint of Disposable Sensors
Every Libre 3 sensor is a single-use electronic device containing a circuit board, a battery, and a plastic casing, all of which go in the trash after 14 days. At the scale CGMs have reached globally, this adds up. A study estimating worldwide CGM waste found that sensor-related disposal generates roughly 580 tons of direct sensor waste per year, which includes plastic casings, electronic circuit boards, and batteries. When you add packaging materials, plastic applicators, and paper inserts, the total rises to over 20,000 tons annually.
14PubMed Central. Quantification of Different Types of Waste and Batteries Associated With the Widespread Usage of Continuous Glucose Monitoring SystemsMost of this waste is not recyclable through standard municipal programs because the sensors contain mixed materials, including lithium batteries embedded in plastic housings. Some users accumulate spent sensors and mail them to specialized electronics recyclers, but there is no manufacturer-sponsored take-back program in most markets. As CGM adoption continues to grow, driven both by expanding insurance coverage and by the non-diabetic wellness market, the waste problem will grow proportionally. It is an area where the industry has been conspicuously quiet, and one where regulatory pressure may eventually force changes in product design or disposal infrastructure.
Data Sharing and Privacy Considerations
The Libre 3 sends all its data to the FreeStyle LibreLink app on your phone, and from there it can sync to Abbott’s cloud platform, LibreView, where your healthcare provider can review your glucose trends remotely. This connectivity is genuinely useful for clinical management, especially between appointments, but it also means your minute-by-minute glucose data lives on external servers.
Research into how people feel about wearable health data has found that most users are not especially worried about sensor data privacy in general, with one consistent exception: insurance companies. Participants in qualitative studies expressed concern that glucose data could be used by insurers to deny coverage, raise premiums, or make adverse decisions about their policies.
15PubMed Central. Addressing privacy concerns for mobile and wearable devices sensors: Small-group interviews with healthy adults and cancer survivorsIn the United States, health data collected by medical devices is covered under HIPAA when held by healthcare providers or insurers, but the regulatory picture gets murkier for data held by the device manufacturer’s app and cloud infrastructure. Abbott’s privacy policy outlines how they handle data, but the practical reality is that detailed, continuous glucose records are among the most granular health datasets a person can generate. If you are someone who thinks carefully about data privacy, it is worth reviewing what you are consenting to when you set up the app and connect it to cloud services.